Press release - For immediate release
May 10, 2024 - 5:45 pm CEST
Disclosure of total number of voting rights and number of shares in the
capital as of April 30th, 2024
Pursuant to article L-223-8 II of the French "code de Commerce" and
223-16 of the AMF's General Regulations.
Sophia Antipolis, France
Total number of shares | 18,418,233 |
Number of real voting rights* | 18,346,685 |
(excluding treasury shares**) | |
Theoretical number of voting rights* | 18,298,337 |
(including treasury shares**) | |
(*) Class E preference shares are non-voting
- pursuant to article 223-11 of the AMF's General Regulations
About Median Technologies: Pioneering in innovative imaging solutions and services, Median Technologies harnesses cutting-edge AI to elevate the accuracy of early cancer diagnoses and cancer treatments. Median's offerings, including iCRO for medical image analysis and management in oncology trials and eyonis™, AI/ML tech-based suite of software as medical devices (SaMD), empower biopharmaceutical entities and clinicians to advance patient care and expedite novel therapies. The French-based company, with a presence in the U.S. and China, is listed on the Euronext Growth market (ISIN:
FR0011049824, ticker: ALMDT). Median is eligible for the French SME equity savings plan scheme (PEA-PME).
For more information: www.mediantechnologies.com
Contacts
Median Technologies | Press - ALIZE RP | Investors - ACTIFIN |
Emmanuelle Leygues | Caroline Carmagnol | Ghislaine Gasparetto |
Head of Corporate Marketing & Financial | +33 6 64 18 99 59 | +33 6 21 10 49 24 |
Communications | median@alizerp.com | ghislaine.gasparetto@seitosei-actifin.com |
+33 6 10 93 58 88 | ||
emmanuelle.leygues@mediantechnologies.com |
1 | P a g e
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Median Technologies SA published this content on 10 May 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 10 May 2024 17:14:08 UTC.